scholarly journals The Potential of Differentiation-Related Gene-1 (DRG1) as a Biomarker for Metastasis of Estrogen Receptor-Positive Breast Cancer

2021 ◽  
pp. 162-169
Author(s):  
Hillary Bor ◽  
Esther N. Maina ◽  
Benson Nyambega ◽  
Kirtika Tushar Patel ◽  
Charles Ochieng’ Olwal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Age Distribution ◽  
Breast Cancer Metastasis ◽  
Related Gene ◽  
Ki 67 ◽  
Potential Biomarker ◽  
Histology Grade ◽  
Er Positive ◽  
Positive Breast Cancer

Introduction: Breast cancer is major burden worldwide and the majority of breast cancers express estrogen receptors (ER) suggesting a high dependence on estrogen hormone. Age is among the major determinants of breast cancer development, however, although Western Kenya is one of the areas with high breast cancer cases, age distribution of ER-positive breast cancer in the sub-region remains largely undocumented. Differentiation-related gene-1 (DRG1) is a metastasis suppressor and thus a potential biomarker for predicting level of metastasis but its potential application in assessing extent of metastasis of ER positive breast cancer has not been fully explored. This study therefore investigated the age distribution and the potential of expression of DRG1 in assessing metastasis of ER positive breast cancer. Materials and Methods: Breast cancer tumour blocks archived in safe cabins in the histology laboratory section, Moi Teaching and Referral hospital, Eldoret, Kenya were used. Clinico-pathological parameters such as histology grade, tumor size, which are associated with metastatic cancer, were assessed using the archived clinico-pathological reports and/or histological analysis of the tumour blocks. Expression of DRG1 and Ki-67 proteins were determined using immunohistochemistry. Results: ER positive breast cancer was predominant among women aged 40 and 50 years. No association was observed between immunohistochemical expression of DRG1 and parameters such as histology grade, tumor size or expression of Ki-67 protein expressed DRG1 (p > 0.05). Conclusion: The findings suggest that expression of DRG1 protein is not associated with parameters that indicate breast cancer metastasis. Thus, DRG1 expression is not a potential biomarker candidate for ER positive breast cancer metastasis. However, since the small sample size was used, further research using larger prospective study is necessary to support the present findings.

scholarly journals Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer

2011 ◽  
Vol 22 (3) ◽  
pp. 582-587 ◽  
Author(s):  
A. DeCensi ◽  
A. Guerrieri-Gonzaga ◽  
S. Gandini ◽  
D. Serrano ◽  
M. Cazzaniga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Labeling Index ◽  
Short Term ◽  
Ki 67 ◽  
Er Positive ◽  
Positive Breast Cancer

scholarly journals Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Janghee Lee ◽  
Chihwan Cha ◽  
Sung Gwe Ahn ◽  
Dooreh Kim ◽  
Soeun Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Stratification ◽  
Postmenopausal Women ◽  
Clinical Treatment ◽  
Labelling Index ◽  
Significant Prognostic Factor ◽  
Ki 67 ◽  
Cox Regression Analysis ◽  
Er Positive ◽  
Positive Breast Cancer

Abstract This study aimed to validate the Clinical Treatment Score post-5 years (CTS5)-based risk stratification in a cohort comprising pre- and postmenopausal patients with estrogen receptor (ER)–positive breast cancer. We investigated the clinicopathologic parameters including Ki-67 labelling index (LI) to identify factors affecting late distant recurrence (DR). Women with ER-positive breast cancer who were free of DR for 5 years were identified between January 2004 and December 2009. We investigated the risk of late DR (5–10 years) according to the CTS5 risk group. Cox regression analysis was used to determine the prognostic performance of CTS5 and identify factors associated with late DR. In all, 680 women were included. Of these, 379 (55.7%) were premenopausal and 301 (44.3%) were postmenopausal. At a median follow-up of 118 months, 32 women had late DR. CTS5 was a significant prognostic factor for late DR in both pre- and postmenopausal women. In the low CTS5 group, high Ki-67 LI (> 20%) was a significant risk factor for late DR. CTS5 is a useful tool for assessing the risk of late DR in pre- and postmenopausal women with ER-positive breast cancer. Extended endocrine therapy can be considered in patients with high Ki-67 LI (> 20%) in the low CTS5 group.

scholarly journals Chemosensitivity based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

2020 ◽  
Author(s):  
Joohyun Woo ◽  
Se Jeong Oh ◽  
Jeong-Yoon Song ◽  
Byung Joo Chae ◽  
Jung Eun Choi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Pathologic Complete Response ◽  
Young Patients ◽  
Complete Response ◽  
Negative Group ◽  
Ki 67 ◽  
Positive Group ◽  
Er Positive ◽  
Positive Breast Cancer

Abstract Background In estrogen receptor (ER)-positive breast cancer, young age is associated with poor prognosis. Several reports have suggested hormonal mechanism as the possible reason. Conversely, very young patients respond better to chemotherapy, and chemotherapy is less effective in ER-positive tumors than in ER-negative tumors. The authors tried to evaluate the chemoinsensitivity of very young patients with ER-positive breast cancer by pathologic complete response (pCR) after neoadjuvant chemotherapy excluding the effect of endocrine treatment to the extent possible.Methods We collected individual patient data from 1992 to 2013 from the Korean Breast Cancer Society (KBCS). Total 1,048 ER-positive and 797 ER-negative patients aged <50 years who had been treated with neoadjuvant chemotherapy were included for analysis. We compared the pathologic complete response (pCR) rate between patients aged <35 years with ER-positive tumors and the other groups.Results The proportion of very young patient aged <35years was 14% in ER-positive group and 16.8% in ER-negative group. Although most chracteristics of tumors according to age were comparable in both groups, tumors with high Ki-67 expression were more common in patients under 35years of age than in those aged 35-49years in both groups (P = 0.001). Breast conservation rates were not significantly different according to age in two groups (44.2% vs. 46.8% in ER-positive group, 55.2% vs. 48.0% in ER-negative group). pCR rates of both breasts and axilla were not significantly different according to age in ER-positive group (P=0.71) but significantly better in patients aged <35years in ER-negative group (P=0.009). After adjusting for confounding variables, young patients maintained the higher probability of pCR than older patients in ER-negative tumors. However, the pCR rate did not differ according to age in ER-positive tumors. Conclusions Chemotherapy response based on pCR rates was not better in young patients (<35 years) with ER-positive breast cancer than in older premenopausal patients with ER-positive advanced breast cancer. Young age cannot be a predictive factor of chemosensitivity in ER-positive breast cancer. Different biological characteristics such as high Ki-67 proliferative index should be considered.Trial registration: retrospectively registered

scholarly journals CXCR4 and Axillary Lymph Nodes: Review of a Potential Biomarker for Breast Cancer Metastasis

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
David Hiller ◽  
Quyen D. Chu
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Metastasis ◽  
Breast Cancer Diagnosis ◽  
Breast Cancer Metastasis ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Peripheral Lymph ◽  
Potential Biomarker ◽  
Node Metastases

CXCR4 is a 7-transmembrane G-protein chemokine receptor that allows for migration of hematopoietic cells from the bone marrow to the peripheral lymph nodes. Research has shown CXCR4 to be implicated in the invasion and metastasis of several cancers, including carcinoma of the breast. CXCL12 is the ligand for CXCR4 and is highly expressed in areas common for breast cancer metastasis, including the axillary lymph nodes. Axillary lymph nodes positive for breast carcinoma have been an important component of breast cancer diagnosis, treatment, and subsequent research. The goal of this paper is to analyze the literature that has explained the pathways from CXCR4 expression to breast cancer metastasis of the lymph nodes and the prognostic and/or predictive implications of lymph node metastases in the presence of elevated CXCR4.

Structural Maintenance of Chromosomes 1A (SMC1A) regulated by KIAA1429 in m6A-independent manner promotes EMT progress in breast cancer

2021 ◽  
Author(s):  
Xu Zhang ◽  
Xin-Yuan Dai ◽  
Jia-Yi Qian ◽  
Feng Xu ◽  
Zhang-Wei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Cancer Metastasis ◽  
Breast Cancer Metastasis ◽  
Luciferase Reporter ◽  
Migration And Invasion ◽  
Western Blots ◽  
Potential Biomarker

Abstract Background As a component in the m6A ‘writers’, KIAA1429 was reported to promote breast cancer proliferation and growth in m6A-independent manners. However, the related mechanism of KIAA1429 in breast cancer metastasis have not been reported. Methods Western blots and quantitative real-time PCR were carried out to verify the expression of KIAA1429 in breast cancer cells SUM1315 and ZR-75-1 after KIAA1429 knockdown or overexpression. Transwell and in vivo metastasis assay were conducted to investigate the effects of KIAA1429 on migration and invasion of breast cancer cells. RIP and REMSA assay was performed to explore the direct correlation between KIAA1429 and SMC1A mRNA. ChIP assay combined with luciferase reporter assay were apply to explore the direct binding between SMC1A and SNAIL promotor region. Results KIAA1429 could significantly promote the migration and invasion of breast cancer cells. Knockdown of KIAA1429 could impede breast cancer metastasis in nude mice in vivo. The level of SNAIL expression and EMT progress was positively related with KIAA1429. Knockdown of KIAA1429 induced cell migration, invasion and EMT progress could be reversed by the upregulation of SNAIL. However, SMC1A, not KIAA1429 bound with SNAIL promoter region directly and promoted the transcription of SNAIL. Then, KIAA1429 could bind to the motif in the 3′-UTR of SMC1A mRNA directly and enhanced SMC1A mRNA stability. Conclusions In conclusion, our study revealed a novel mechanism of the KIAA1429/SMC1A/SNAIL axis in the regulation of invasion and metastasis of breast cancer, which may provide a potential biomarker and therapeutic target for breast cancer. Moreover, it firstly provided compelling evidences that KIAA1429 could regulate the targeted gene expression at posttranscriptional levels as an RNA-binding protein, unrelated the m6A modification.

Sign in / Sign up

Export Citation Format

Share Document